NEXGEL closes Celularity regenerative biomaterials acquisition, sees revenue roughly tripling to about $35 million and immediate profitability accretion
Acquisition funded by new $5.5 million strategic investment from Sequence LifeScience via a convertible note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.